Barry Labinger has joined Checkmate Pharmaceuticals as president and CEO, the Cambridge, MA, company announced Wednesday. Labinger comes to the cancer drug developer from Biothera Pharmaceuticals, where he was president and CEO. His experience also includes leadership positions at Human Genome Sciences, 3M Pharmaceuticals, and Immunex.
Labinger is succeeding Arthur Krieg, who is shifting to a new role as chief scientific officer. Both Labinger and Krieg will hold seats on Checkmate’s board of directors. Checkmate also announced on Wednesday $22 million in new financing led by new investor Decheng Capital. The company has advanced lead drug candidate CMP-001 into early-stage clinical testing as a treatment for melanoma.
